Researchers at ChristianaCare’s Cawley Center for Translational Cancer Research at the Helen F. Graham Cancer Center & Research Institute have demonstrated for the first time that microRNA expression leads to a diversity of cancer stem cells within a colorectal cancer tumor. This diversity of cancer cells may explain why advanced colorectal cancer is difficult to treat.
In a phase III NRG‑GY018 trial investigating Keytruda (pembrolizumab) in combination with standard of care chemotherapy (carboplatin and paclitaxel) for the first-line treatment of patients with stage III-IV or recurrent endometrial carcinoma whose cancer was either mismatch repair proficient or mismatch repair deficient, the Keytruda regimen demonstrated a statistically significant and clinically meaningful improvement in progression-free survival for patients, regardless of mismatch repair status.
In the phase III RUBY clinical trial, the Jemperli regimen showed a statistically significant and clinically meaningful improvement in progression free survival in the mismatch repair deficient/microsatellite instability-high population and in the overall population.
Researchers with the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborators have shown that immature natural killer cells are present in patients with triple-negative breast cancer and likely promote, instead of inhibit, disease progression in this cancer type.
An interim analysis of NATALEE, a phase III trial evaluating Kisqali (ribociclib) plus endocrine therapy in a broad population of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer at risk of recurrence demonstrated positive topline results.
Results of a multi-institutional clinical trial recently published in the Journal of Clinical Oncology show that surgically removing affected lymph nodes in the retroperitoneum of patients with early metastatic seminoma is an effective alternative to chemotherapy and radiation, with fewer long-term side effects.
A study published in Blood Advances demonstrates that patients with blood cancers experienced a significant improvement in their reported well-being six months after receiving CAR T-cell therapy.
By investigating non-antibiotic-disrupted microbiomes, MD Anderson Cancer Center researchers developed a machine-learning algorithm that can predict long-term response to CAR T therapy using microbiome-based biomarkers. The study was published in Nature Medicine.
The breast tumors of Asian, Black and white patients have very different cellular, microbial, and genomic features that could potentially be used to personalize care or predict disease progression, according to research by investigators at the Johns Hopkins Kimmel Cancer Center.
Researchers at the University of Cincinnati developed an approach to radionuclide therapy which uses engineered bacteria to target cancer cells without endogenously targetable receptors.
